サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513903

嚢胞性線維症治療薬の世界市場

Cystic Fibrosis Therapeutics

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.81円
嚢胞性線維症治療薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

嚢胞性線維症治療薬の世界市場は2030年までに468億米ドルに達する見込み

2023年に175億米ドルと推定される嚢胞性線維症治療薬の世界市場は、2023～2030年の分析期間中に15.1%のCAGRで成長し、2030年には468億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである嚢胞性線維症治療薬は、CAGR 15.5%を記録し、分析期間終了までに421億米ドルに達すると予測されます。嚢胞性線維症治療機器セグメントの成長率は、分析期間中CAGR 13.0%と推定されます。

米国市場は45億米ドル、中国はCAGR19.8%で成長予測

米国の嚢胞性線維症治療薬市場は2023年に45億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR19.8%で推移し、2030年には予測市場規模121億米ドルに達すると予測されます。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.0%と12.7%と予測されています。欧州では、ドイツがCAGR 11.3%で成長すると予測されています。

嚢胞性線維症治療薬-主要動向と促進要因

嚢胞性線維症（CF）は、主に呼吸器系と消化器系に影響を及ぼす遺伝病であり、気道を詰まらせ、重篤な呼吸器系および消化器系の合併症を引き起こす、濃厚で粘着性の粘液の産生が特徴です。嚢胞性線維症の治療法は、過去数十年の間に大きく発展し、純粋な対症療法から、根本的な遺伝的欠陥に対処することを目的としたより的を絞った治療へと移行しています。CF治療薬の開発は、疾患の原因であるCFTR遺伝子変異に対する理解の進歩によって推進され、欠損タンパク質の機能を改善するCFTRモジュレーターの創製につながった。ivacaftor、lumacaftor、tezacaftorなどのこれらのモジュレーターは、特定の遺伝子プロファイルに合わせた個別化医療を提供することで治療に革命をもたらし、患者の転帰と生活の質を大幅に改善しました。

嚢胞性線維症の新たな治療法には、新規の抗炎症薬、粘液クリアランス治療、遺伝子治療も含まれます。抗炎症剤は、CF患者の肺障害の原因となる慢性炎症を抑えることを目的としています。高張食塩水やドルナーゼアルファなどの粘液クリアランス治療は、粘液を薄め、気道からの粘液の除去を促進し、呼吸機能を改善します。欠陥のあるCFTR遺伝子を修正または置換する遺伝子治療は、治癒の可能性が期待されています。最近の臨床試験では、CRISPR/Cas9のような遺伝子編集技術により、嚢胞性線維症の原因となる遺伝子変異を標的として修復することができ、有望な結果が得られています。さらに、吸入療法や脂質ナノ粒子などの送達方法の進歩により、これらの治療の有効性と利用しやすさが向上しています。

嚢胞性線維症市場の成長は、認知度や診断率の上昇、遺伝子研究の進歩、医薬品開発への多額の投資など、いくつかの要因によってもたらされます。特に先進諸国では嚢胞性線維症の有病率が上昇しており、効果的な治療に対する需要が高まっています。新生児スクリーニングや遺伝子検査などの診断技術の向上により、この疾患の管理には欠かせない早期発見・早期介入が可能となっています。さらに、製薬業界による革新的な治療法の充実したパイプラインは、官民双方からの多額の資金援助に支えられ、新たな治療法の開発と承認を加速させています。学術機関、バイオテクノロジー企業、患者支援団体間の協力により、よりダイナミックで生産的な研究環境が育まれています。さらに、希少疾病用医薬品の指定や迅速な審査といった規制上の優遇措置も、CF治療薬の開発を後押ししています。これらの要因が相まって、嚢胞性線維症治療薬市場は拡大しており、この困難な疾患に対するより良い管理と治療法の可能性に期待が寄せられています。

調査対象企業の例（全56件）

  • AbbVie Inc.
  • Galapagos NV
  • Genentech
  • Gilead Sciences Inc.
  • Novartis AG
  • Vertex Pharmaceuticals Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6233

Global Cystic Fibrosis Therapeutics Market to Reach US$46.8 Billion by 2030

The global market for Cystic Fibrosis Therapeutics estimated at US$17.5 Billion in the year 2023, is expected to reach US$46.8 Billion by 2030, growing at a CAGR of 15.1% over the analysis period 2023-2030. Cystic Fibrosis Medication, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$42.1 Billion by the end of the analysis period. Growth in the Cystic Fibrosis Treatment Devices segment is estimated at 13.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.5 Billion While China is Forecast to Grow at 19.8% CAGR

The Cystic Fibrosis Therapeutics market in the U.S. is estimated at US$4.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$12.1 Billion by the year 2030 trailing a CAGR of 19.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 12.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.3% CAGR.

Cystic Fibrosis Therapeutics - Key Trends and Drivers

Cystic fibrosis (CF) is a genetic disorder that primarily affects the respiratory and digestive systems, characterized by the production of thick, sticky mucus that can clog airways and lead to severe respiratory and gastrointestinal complications. The therapeutic landscape for cystic fibrosis has evolved significantly over the past few decades, shifting from purely symptomatic treatments to more targeted therapies aimed at addressing the underlying genetic defects. The development of CF therapeutics has been propelled by advancements in our understanding of the CFTR gene mutations that cause the disease, leading to the creation of CFTR modulators that improve the function of the defective protein. These modulators, such as ivacaftor, lumacaftor, and tezacaftor, have revolutionized treatment by offering personalized medicine approaches tailored to specific genetic profiles, significantly improving patient outcomes and quality of life.

Emerging therapies for cystic fibrosis also include novel anti-inflammatory agents, mucus clearance treatments, and gene therapies. Anti-inflammatory drugs aim to reduce the chronic inflammation that contributes to lung damage in CF patients. Mucus clearance treatments, such as hypertonic saline and dornase alfa, help thin the mucus and facilitate its removal from the airways, thus improving respiratory function. Gene therapy, which seeks to correct or replace the defective CFTR gene, holds promise for a potential cure. Recent clinical trials have shown encouraging results with gene-editing technologies like CRISPR/Cas9, which can target and repair the genetic mutations responsible for cystic fibrosis. Additionally, advancements in delivery methods, such as inhalation therapies and lipid nanoparticles, are enhancing the effectiveness and accessibility of these treatments.

The growth in the cystic fibrosis therapeutics market is driven by several factors, including increasing awareness and diagnosis rates, advancements in genetic research, and significant investments in drug development. The rising prevalence of cystic fibrosis, particularly in developed countries, has led to greater demand for effective treatments. Improved diagnostic techniques, such as newborn screening and genetic testing, are enabling earlier detection and intervention, which are crucial for managing the disease. Moreover, the pharmaceutical industry's robust pipeline of innovative therapies, supported by substantial funding from both public and private sectors, is accelerating the development and approval of new treatments. Collaboration between academic institutions, biotech companies, and patient advocacy groups is fostering a more dynamic and productive research environment. Additionally, regulatory incentives, such as orphan drug designations and expedited review processes, are encouraging the development of CF therapeutics. These factors collectively contribute to the expanding cystic fibrosis therapeutics market, offering hope for better management and potential cures for this challenging condition.

Select Competitors (Total 56 Featured) -

  • AbbVie Inc.
  • Galapagos NV
  • Genentech
  • Gilead Sciences Inc.
  • Novartis AG
  • Vertex Pharmaceuticals Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Cystic Fibrosis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cystic Fibrosis Spurs Growth
    • Advances in Genetic Research Propel Market Expansion
    • Improved Diagnostic Techniques Drive Early Detection and Treatment
    • Increasing Awareness Campaigns Throw the Spotlight on Cystic Fibrosis
    • Advancements in Gene Therapy Techniques Propel Growth
    • Improved Drug Delivery Methods Generate Opportunities for Enhanced Treatments
    • Newborn Screening Programs Drive Adoption of Early Intervention Strategies
    • Personalized Medicine Trends Spur Growth in Targeted Therapies
    • Chronic Inflammation Management Technologies Propel Market Expansion
    • Mucus Clearance Innovations Generate Demand for Respiratory Function Improvement
    • Technological Innovations in CRISPR/Cas9 Editing Create New Treatment Possibilities
    • Adoption of Inhalation Therapies Strengthens the Business Case for Non-Invasive Treatments
    • Economic Burden of CF Prompts Demand for Cost-Effective Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cystic Fibrosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Treatment Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Treatment Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Treatment Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • INDIA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AFRICA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION